10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: Results for 1,100 Patients

International Journal of Radiation Oncology Biology Physics

Volumn 80, Issue 5, 2011, Pages 1323-1329

  Crook, Juanita ^a   Borg, Jette ^a   Evans, Andrew ^a   Toi, Ants ^a   Saibishkumar, E P ^a   Fung, Sharon ^a   Ma, Clement ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Brachytherapy; Prostate neoplasms; Prostate specific antigen; Radiotherapy

Indexed keywords

BRACHYTHERAPY; DISEASE FREE SURVIVAL; EXTERNAL RADIOTHERAPY; GLEASON SCORES; HAZARD RATIO; INDEPENDENT PREDICTORS; INTERNATIONAL PROSTATE SYMPTOM SCORES; IODINE-125; LOCAL FAILURE; MULTI VARIATE ANALYSIS; NEOADJUVANT HORMONAL THERAPY; PRINCESS MARGARET HOSPITALS; PROPORTIONAL HAZARDS; PROSTATE BRACHYTHERAPY; PROSTATE CANCERS; PROSTATE NEOPLASMS; PROSTATE SPECIFIC ANTIGEN; TRANSRECTAL ULTRASOUND; UNIVARIATE;

ANTIGENS; DISEASES; INDUSTRIAL CHEMICALS; IODINE; MULTIVARIANT ANALYSIS; ONCOLOGY;

RADIOTHERAPY;

ANTINEOPLASTIC AGENT; IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ERECTILE DYSFUNCTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; RADIATION DOSE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ONTARIO; PENILE ERECTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; URINATION DISORDERS;

EID: 79960077352     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.04.038     Document Type: Article

References (38)

1. K. Wallace, N. Fleshner, M. Jewett, J. Basiuk, and J. Crook Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: The Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial J Clin Oncol 24 25 2006 4158 4162 (Pubitemid 46622293)
2. W.J. Morris, M. Keyes, D. Palma, I. Spadinger, M.R. McKenzie, and A. Agranovich Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer Urology 73 4 2009 860 867
3. L. Potters, C. Morgenstern, E. Calugaru, P. Fearn, A. Jassal, and J. Presser 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer J Urol 173 5 2005 1562 1566 (Pubitemid 40524771)
4. P.D. Grimm, J.C. Blasko, J.E. Sylvester, R.M. Meier, and W. Cavanagh 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy Int J Radiat Oncol Biol Phys 51 1 2001 31 40 (Pubitemid 32758858)
5. J. Crook, H. Lukka, L. Klotz, N. Bestic, M. Johnston for the Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer CMAJ 164 7 2001 975 981 (Pubitemid 34412225)
6. M.J. Barry, F.J. Fowler Jr., M.P. O'Leary, R.C. Bruskewitz, H.L. Holtgrewe, and W.K. Mebust The American urological association symptom index for benign prostatic hyperplasia. The measurement committee of the american urological association J Urol 148 5 1992 1549 1557
7. R.C. Rosen, J.C. Cappelleri, M.D. Smith, J. Lipsky, and B.M. Pena Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction Int J Impot Res 11 6 1999 319 326 (Pubitemid 30052683)
8. R. Nath, L.L. Anderson, G. Luxton, K.A. Weaver, J.F. Williamson, and A.S. Meigooni Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM radiation therapy committee task group no. 43. American Association of Physicists in Medicine Med Phys 22 2 1995 209 234
9. J.M. Crook, L. Potters, R.G. Stock, and M.J. Zelefsky Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk Brachytherapy 4 3 2005 186 194 (Pubitemid 41338051)
10. M. Roach III, G. Hanks, H. Thames Jr., P. Schellhammer, W.U. Shipley, and G.H. Sokol Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO phoenix consensus conference Int J Radiat Oncol Biol Phys 65 4 2006 Jul 15 965 974
11. J. Crook, C. Gillan, I. Yeung, L. Austen, M. McLean, and G. Lockwood PSA kinetics and PSA bounce following permanent seed prostate brachytherapy Int J Radiat Oncol Biol Phys 69 2 2007 Oct 1 426 433 (Pubitemid 47380099)
12. J.E. Sylvester, P.D. Grimm, J.C. Blasko, J. Millar, P.F. Orio III, and S. Skoglund 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience Int J Radiat Oncol Biol Phys 67 1 2007 57 64 (Pubitemid 44959493)
13. R.G. Stock, N.N. Stone, J.A. Cesaretti, and B.S. Rosenstein Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results Int J Radiat Oncol Biol Phys 64 2 2006 527 533 (Pubitemid 43083442)
14. L. Potters, M. Roach III, B.J. Davis, R.G. Stock, J.P. Ciezki, and M.J. Zelefsky Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable Int J Radiat Oncol Biol Phys 76 4 2010 1061 1065
15. N.N. Stone, R.G. Stock, J.A. Cesaretti, and P. Unger Local control following permanent prostate brachytherapy: Effect of high biologically effective dose on biopsy results and oncologic outcomes Int J Radiat Oncol Biol Phys 2009 Jul 23
16. J. Crook, M. Milosevic, P. Catton, I. Yeung, T. Haycocks, and T. Tran Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy Brachytherapy 1 2 2002 66 73 (Pubitemid 37329415)
17. A.Y. Ho, R.J. Burri, J.A. Cesaretti, N.N. Stone, and R.G. Stock Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy Int J Radiat Oncol Biol Phys 75 1 2009 16 22
18. R.G. Stock, T.J. Klein, J.A. Cesaretti, and N.N. Stone Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy Int J Radiat Oncol Biol Phys 74 3 2009 753 758
19. D.A. Barocas, J.E. Cowan, J.A. Smith Jr., P.R. Carroll for the CaPSURE Investigators What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database J Urol 180 4 2008 1330 1334
20. L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 1 2010 126 131
21. A. Nichol, P. Chung, G. Lockwood, T. Rosewall, L. Divanbiegi, and J. Sweet A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy Radiother Oncol 76 1 2005 11 17 (Pubitemid 41096509)
22. P.A. Kupelian, J. Ciezki, C.A. Reddy, E.A. Klein, and A. Mahadevan Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer Int J Radiat Oncol Biol Phys 71 1 2008 16 22 (Pubitemid 351491401)
23. O. Cahlon, M.J. Zelefsky, A. Shippy, H. Chan, Z. Fuks, and Y. Yamada Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes Int J Radiat Oncol Biol Phys 71 2 2008 330 337
24. M.J. Zelefsky, Y. Yamada, Z. Fuks, Z. Zhang, M. Hunt, and O. Cahlon Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes Int J Radiat Oncol Biol Phys 71 4 2008 1028 1033
25. J.M. Martin, A. Bayley, R. Bristow, P. Chung, M. Gospodarowicz, and C. Menard Image guided dose escalated prostate radiotherapy: Still room to improve Radiat Oncol 4 2009 50
26. T. Pickles, M. Keyes, and W.J. Morris Brachytherapy or conformal external radiotherapy for prostate cancer: A single-institution matched-pair analysis Int J Radiat Oncol Biol Phys 76 1 2010 43 49
27. C. Martens, G. Pond, D. Webster, M. McLean, C. Gillan, and J. Crook Relationship of the international prostate symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy Brachytherapy 5 1 2006 9 13
28. R.G. Stock, S. Yamalachi, S.J. Hall, and N.N. Stone Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation J Urol 183 2 2010 546 550
29. A. Martinez, R. Galalae, J. Gonzalez, C. Mitchell, G. Gustafson, and G. Kovacs No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose J Urol 170 6 Pt 1 2003 2296 2301 (Pubitemid 37413979)
30. D.C. Beyer, T. McKeough, and T. Thomas Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 61 5 2005 1299 1305
31. J. Crook, N. Fleshner, C. Roberts, and G. Pond Long-term urinary sequelae following 125iodine prostate brachytherapy J Urol 179 1 2008 141 145
32. J. Crook, D. Webster, and D. Virtue 140 sexual function following iodine 125 prostate brachytherapy Radiother Oncol 80 Suppl 1 2006 S41
33. N. Mabjeesh, J. Chen, A. Beri, A. Stenger, and H. Matzkin Sexual function after permanent 125I-brachytherapy for prostate cancer Int J Impot Res 17 1 2005 96 101 (Pubitemid 40300001)
34. G.S. Merrick, W.M. Butler, R.W. Galbreath, R.L. Stipetich, L.J. Abel, and J.H. Lief Erectile function after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 52 4 2002 893 902 (Pubitemid 34223438)
35. N.N. Stone, and R.G. Stock Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years Urology 69 2 2007 338 342 (Pubitemid 46274929)
36. J.D. Schiff, N. Bar-Chama, J. Cesaretti, and R. Stock Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function BJU Int 98 6 2006 1255 1258 (Pubitemid 44721237)
37. J. Crook, S. Malone, G. Perry, Y. Bahadur, S. Robertson, and M. Abdolell Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients Int J Radiat Oncol Biol Phys 48 2 2000 355 367
38. Crook J, Patil N, Ma C, McLean M, Borg J. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009. e-pub ahead of print.